论文部分内容阅读
万古霉素属于糖肽类窄谱抗生素,临床上主要用于治疗耐药金黄色葡萄球菌引起的严重感染,如骨髓炎、肺炎、心内膜炎等。因其不易产生细菌耐药性,受到了越来越多的关注,一直被专家称为“人类对付顽固性耐药菌株的最后一道防线”。但是,万古霉素在临床上有时需要长期大量给药,在体内会产生许多不良反应,如肾功能衰竭、耳毒性、过敏反应等。为了解决万古霉素的毒性问题,提高其疗效,研发万古霉素新剂型成为近年来新药研发的热点之一。通过检索文献,文章就万古霉素载体的研究进展进行综述。
Vancomycin is a narrow-spectrum antibiotics glycopeptide, clinically used mainly for the treatment of drug-resistant Staphylococcus aureus caused by serious infections such as osteomyelitis, pneumonia, endocarditis and so on. Because of its resistance to bacterial resistance, has attracted more and more attention, has been called by experts as “The human last line of defense against resistant strains of bacteria ”. However, vancomycin sometimes needs to be administered in large quantities for a long time in clinical practice. Many adverse reactions occur in the body, such as renal failure, ototoxicity and allergic reactions. In order to solve the problem of vancomycin toxicity and improve its curative effect, the development of new vancomycin dosage forms has become one of the hot spots in the research and development of new drugs in recent years. Through the search of literature, the article reviews the research progress of vancomycin carrier.